Literature DB >> 32632233

Dapagliflozin reduces left ventricular mass.

Gregory B Lim1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32632233     DOI： 10.1038/s41569-020-0417-5

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  1 in total

1.  A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial.

Authors:  Alexander J M Brown; Stephen Gandy; Rory McCrimmon; John Graeme Houston; Allan D Struthers; Chim C Lang
Journal:  Eur Heart J       Date:  2020-09-21       Impact factor: 29.983
  1 in total
  1 in total

1.  Dapagliflozin Guards Against Cadmium-Induced Cardiotoxicity via Modulation of IL6/STAT3 and TLR2/TNFα Signaling Pathways.

Authors:  Marwa M M Refaie; Rehab Ahmed Rifaai; Michael Atef Fawzy; Sayed Shehata
Journal:  Cardiovasc Toxicol       Date:  2022-10-15       Impact factor: 2.755
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.